HEYL antibody - N-terminal region (ARP31866_T100)
- Known as:
- HEYL (anti-) - N-terminal region (ARP31866_T100)
- Catalog number:
- arp31866_t100
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- HEYL antibody - N-terminal region (ARP31866_T100)
Related genes to: HEYL antibody - N-terminal region (ARP31866_T100)
- Gene:
- HEYL NIH gene
- Name:
- hes related family bHLH transcription factor with YRPW motif like
- Previous symbol:
- -
- Synonyms:
- bHLHb33, HEY3, HESR3
- Chromosome:
- 1p34.2
- Locus Type:
- gene with protein product
- Date approved:
- 1999-12-07
- Date modifiied:
- 2019-02-18
Related products to: HEYL antibody - N-terminal region (ARP31866_T100)
Related articles to: HEYL antibody - N-terminal region (ARP31866_T100)
- Genome-wide studies of differential DNA methylation often focus on its role in turning transcription on or off. Here we report some atypical epigenetic/transcription relationships for 92 genes that are highly and preferentially expressed in primary human myoblasts relative to heterologous cell cultures. - Source: PubMed
Publication date: 2026/03/13
Ehrlich Kenneth CLacey MichellePradhan SriharsaEhrlich Melanie - Abdominal aortic aneurysm (AAA) progression is driven by extracellular matrix (ECM) proteolysis and vascular smooth muscle cell loss, processes not captured by diameter-based surveillance. A disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4) is upregulated during early ECM remodeling, making it a compelling target for molecular imaging. - Source: PubMed
Publication date: 2026/03/18
Ranner-Hafferl Marie-Luise H HMangarova Dilyana BHeyl Jennifer LMein JenniferMöckel JanaSchnapauff DirkAuer Timo ACollettini FedericoAdams Lisa CHingst DavidKaufmann Jan OMakowski Marcus RKarst UweHamm BerndBrangsch JuliaKader Avan - Seven eremophilanes, including three previously undescribed compounds, were extracted and purified from whole plants of Ligularia macrophylla. Their structures, including absolute configurations, were characterized by spectroscopic, quantum chemical NMR, and Single-crystal X-ray methods. The antibacterial activity of these compounds was evaluated against Escherichia coli and Bacillus subtilis. Among them, compound 4 exhibited the most potent antibacterial activity against B. subtilis, with an inhibition zone of 30.58 ± 2.63 mm at 256 μg/mL. All compounds showed no activity against E. coli, as their minimum inhibitory concentration (MIC) exceeded 5 mg/mL. - Source: PubMed
Publication date: 2026/03/05
Gao NaLi Guo-LiZha Xiang-TaoYang Hong-YingHe Yi-LinShen Tong - Moderate-to-severe traumatic brain injury (msTBI) is associated with heterogeneous long-term outcomes, yet the dynamic trajectories of functional recovery remain poorly characterized. This study aimed to identify distinct prognostic trajectory subgroups and their risk factors in msTBI patients. A retrospective cohort study was conducted on msTBI patients admitted to our institution. Glasgow Outcome Scale (GOS) scores were assessed at discharge and at 3, 6, 12, and 24 months post-discharge. Latent class growth analysis (LCGA) was employed to identify distinct prognostic trajectories. Univariate analysis and multivariable ordinal regression models were used to identify factors associated with trajectory membership. A total of 401 patients were included in the final analysis. Four distinct prognostic trajectories were identified: (1) Catastrophic Outcome without Recovery (Trajectory 1), (2) Limited Improvement with Unfavorable Outcome (Trajectory 2), (3) Delayed but Sustained Favorable Recovery (Trajectory 3), and (4) Early Stable Favorable Outcome (Trajectory 4). Multivariable ordinal regression analysis identified admission and discharge levels of consciousness (LOC), discharge GOS score, age, and chronic comorbidities as significant independent factors associated with the prognostic trajectories. msTBI patients exhibit heterogeneous long-term recovery patterns that can be classified into four distinct trajectories. Early identification of trajectory membership through baseline clinical characteristics may facilitate personalized rehabilitation strategies and prognostic counseling. - Source: PubMed
Publication date: 2026/01/29
Wang Ren-CiYan JingZhao Jun-JieMa Tian-ChiGuo Wen-HengWang He-RongHan Jing-YiTang Wen-JunWu Feng-BoYin An-AnLin WeiLi XiaHe Ya-Long - Peritoneal metastasis (PM) remains a primary cause of poor prognosis in advanced gastric cancer (GC). While anoikis resistance enables detached tumor cells to survive and promotes invasion and metastasis, its specific mechanisms in GC related PM are not yet fully understood. - Source: PubMed
Publication date: 2026/01/08
Hou DongYu JinhaoXie YequanZhou ShengningZeng JintaoLiang MingtaoZheng FangTan JiananHan Fanghai